Literature DB >> 31434474

Repurposing Eukaryotic Kinase Inhibitors as Colistin Adjuvants in Gram-Negative Bacteria.

William T Barker1, Ansley M Nemeth1, Sara M Brackett1, Akash K Basak1, Courtney E Chandler2, Leigh A Jania3, William J Zuercher4, Roberta J Melander1, Beverly H Koller3, Robert K Ernst2, Christian Melander1.   

Abstract

Kinase inhibitors comprise a diverse cohort of chemical scaffolds that are active in multiple biological systems. Currently, thousands of eukaryotic kinase inhibitors are commercially available, have well-characterized targets, and often carry pharmaceutically favorable toxicity profiles. Recently, our group disclosed that derivatives of the natural product meridianin D, a known inhibitor of eukaryotic kinases, modulated behaviors of both Gram-positive and Gram-negative bacteria. Herein, we expand our exploration of kinase inhibitors in Gram-negative bacilli utilizing three commercially available kinase inhibitor libraries and, ultimately, identify two chemical structures that potentiate colistin (polymyxin E) in multiple strains. We report IMD-0354, an inhibitor of IKK-β, as a markedly effective adjuvant in colistin-resistant bacteria and also describe AR-12 (OSU-03012), an inhibitor of pyruvate dehydrogenase kinase-1 (PDK-1), as a potentiator in colistin-sensitive strains. This report comprises the first description of the novel cross-reactivity of these molecules.

Entities:  

Keywords:  antibiotic adjuvants; colistin; lipid A; multidrug-resistant Gram-negative bacteria

Mesh:

Substances:

Year:  2019        PMID: 31434474      PMCID: PMC6944324          DOI: 10.1021/acsinfecdis.9b00212

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  32 in total

1.  Structural heterogeneity and environmentally regulated remodeling of Francisella tularensis subspecies novicida lipid A characterized by tandem mass spectrometry.

Authors:  Scott A Shaffer; Megan D Harvey; David R Goodlett; Robert K Ernst
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-28       Impact factor: 3.109

Review 2.  Targeting virulence: a new paradigm for antimicrobial therapy.

Authors:  Anne E Clatworthy; Emily Pierson; Deborah T Hung
Journal:  Nat Chem Biol       Date:  2007-09       Impact factor: 15.040

3.  Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria.

Authors:  William T Barker; Sara E Martin; Courtney E Chandler; T Vu Nguyen; Tyler L Harris; Christopher Goodell; Roberta J Melander; Yohei Doi; Robert K Ernst; Christian Melander
Journal:  Bioorg Med Chem       Date:  2017-09-09       Impact factor: 3.641

4.  Tryptamine derivatives disarm colistin resistance in polymyxin-resistant gram-negative bacteria.

Authors:  William T Barker; Courtney E Chandler; Roberta J Melander; Robert K Ernst; Christian Melander
Journal:  Bioorg Med Chem       Date:  2019-03-08       Impact factor: 3.641

5.  Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii.

Authors:  Mark R Pelletier; Leila G Casella; Jace W Jones; Mark D Adams; Daniel V Zurawski; Karsten R O Hazlett; Yohei Doi; Robert K Ernst
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

6.  OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.

Authors:  Shuhong Zhang; Attaya Suvannasankha; Colin D Crean; Valerie L White; Amy Johnson; Ching-Shih Chen; Sherif S Farag
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

Review 7.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

8.  AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments.

Authors:  Anna C Jacobs; Mitchell G Thompson; Chad C Black; Jennifer L Kessler; Lily P Clark; Christin N McQueary; Hanan Y Gancz; Brendan W Corey; Jay K Moon; Yuanzheng Si; Matthew T Owen; Justin D Hallock; Yoon I Kwak; Amy Summers; Charles Z Li; David A Rasko; William F Penwell; Cary L Honnold; Matthew C Wise; Paige E Waterman; Emil P Lesho; Rena L Stewart; Luis A Actis; Thomas J Palys; David W Craft; Daniel V Zurawski
Journal:  MBio       Date:  2014-05-27       Impact factor: 7.867

9.  Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Authors:  Daniela Bressanin; Camilla Evangelisti; Francesca Ricci; Giovanna Tabellini; Francesca Chiarini; Pier Luigi Tazzari; Fraia Melchionda; Francesca Buontempo; Pasqualepaolo Pagliaro; Andrea Pession; James A McCubrey; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-08

10.  Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.

Authors:  Bing Fan; Jie Guan; Xiumei Wang; Yulong Cong
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

View more
  9 in total

1.  Eukaryotic phosphatase inhibitors enhance colistin efficacy in gram-negative bacteria.

Authors:  William T Barker; Leigh A Jania; Roberta J Melander; Beverly H Koller; Christian Melander
Journal:  Chem Biol Drug Des       Date:  2020-06-19       Impact factor: 2.817

2.  Benzimidazole Isosteres of Salicylanilides Are Highly Active Colistin Adjuvants.

Authors:  Haoting Li; Anne E Mattingly; Leigh A Jania; Richard Smith; Roberta J Melander; Robert K Ernst; Beverley H Koller; Christian Melander
Journal:  ACS Infect Dis       Date:  2021-11-09       Impact factor: 5.084

3.  Inhibitors of O-Acetylserine Sulfhydrylase with a Cyclopropane-Carboxylic Acid Scaffold Are Effective Colistin Adjuvants in Gram Negative Bacteria.

Authors:  Giannamaria Annunziato; Costanza Spadini; Marialaura Marchetti; Nina Franko; Marialaura Pavone; Mattia Iannarelli; Agostino Bruno; Marco Pieroni; Stefano Bettati; Clotilde Silvia Cabassi; Barbara Campanini; Gabriele Costantino
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-20

4.  Structure-Function Studies on IMD-0354 Identifies Highly Active Colistin Adjuvants.

Authors:  Ansley M Nemeth; Akash K Basak; Alexander W Weig; Santiana A Marrujo; William T Barker; Leigh A Jania; Tyler A Hendricks; Ashley E Sullivan; Patrick M O'Connor; Roberta J Melander; Beverly H Koller; Christian Melander
Journal:  ChemMedChem       Date:  2019-12-04       Impact factor: 3.466

5.  Antibiotic Adjuvant Activity Revealed in a Photoaffinity Approach to Determine the Molecular Target of Antipyocyanin Compounds.

Authors:  Zinan Zhang; Dominic Ortega; Anthony Rush; Lauren R Blankenship; Zi Jun Cheng; Rebecca E Moore; Minh L N Tran; Lucero G Sandoval; Kareem Aboulhosn; Seiichiro Watanabe; Kendra S Cortez; David H Perlman; Martin F Semmelhack; Laura C Miller Conrad
Journal:  ACS Infect Dis       Date:  2021-02-15       Impact factor: 5.084

Review 6.  Pseudomonas aeruginosa Toxin ExoU as a Therapeutic Target in the Treatment of Bacterial Infections.

Authors:  Daniel M Foulkes; Keri McLean; Atikah S Haneef; David G Fernig; Craig Winstanley; Neil Berry; Stephen B Kaye
Journal:  Microorganisms       Date:  2019-12-16

7.  A novel colistin adjuvant identified by virtual screening for ArnT inhibitors.

Authors:  Francesca Ghirga; Roberta Stefanelli; Luca Cavinato; Alessandra Lo Sciuto; Silvia Corradi; Deborah Quaglio; Andrea Calcaterra; Bruno Casciaro; Maria Rosa Loffredo; Floriana Cappiello; Patrizia Morelli; Alberto Antonelli; Gian Maria Rossolini; Marialuisa Mangoni; Carmine Mancone; Bruno Botta; Mattia Mori; Fiorentina Ascenzioni; Francesco Imperi
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

8.  AR-12 Exhibits Direct and Host-Targeted Antibacterial Activity toward Mycobacterium abscessus.

Authors:  Shaoyan Zhang; Yuzhen Zou; Qi Guo; Jianhui Chen; Liyun Xu; Xiaoyu Wan; Zhemin Zhang; Bing Li; Haiqing Chu
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  ent-Beyerane Diterpenes as a Key Platform for the Development of ArnT-Mediated Colistin Resistance Inhibitors.

Authors:  Deborah Quaglio; Maria Luisa Mangoni; Roberta Stefanelli; Silvia Corradi; Bruno Casciaro; Valeria Vergine; Federica Lucantoni; Luca Cavinato; Silvia Cammarone; Maria Rosa Loffredo; Floriana Cappiello; Andrea Calcaterra; Silvia Erazo; Francesca Ghirga; Mattia Mori; Francesco Imperi; Fiorentina Ascenzioni; Bruno Botta
Journal:  J Org Chem       Date:  2020-08-10       Impact factor: 4.354

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.